tbResList Print — BF Bufalin/Huachansu

Description: <b>Bufalin/Huachansu</b> is a component from Chinese toad venom. Bufalin is classified as a cardiac glycoside, specifically a type of bufadienolide.<br>
<br>
Pathways:<br>
-release of cytochrome c and subsequent activation of caspases<br>
-enhance the expression of death receptors<br>
-inhibit the PI3K/Akt/mTOR<br>
-modulate the MAPK/ERK pathway<br>
-inhibit NF-κB signaling<br>
-induce cell cycle arrest at different checkpoints (commonly G0/G1 or G2/M)<br>
-elevate intracellular ROS levels<br>
-interfere with the Wnt/β-catenin signaling pathway<br>
-modulate autophagy, a process that can either promote cell survival or lead to cell death <br>
-Stabilization or activation of p53 <br>

<p><b>Bufalin</b> — Bufalin is a steroidal cardiotonic toxin and anticancer lead compound, classically isolated from toad venom (ChanSu / Huachansu) and belonging to the bufadienolide subclass of cardiac glycosides. It is commonly abbreviated <b>BF</b>. In cancer research, bufalin is best understood as a pleiotropic signaling disruptor whose most central pharmacology is linked to Na⁺/K⁺-ATPase engagement, with downstream effects on survival signaling, mitochondrial death pathways, redox stress, stemness, invasion, and therapy resistance. </p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Na⁺/K⁺-ATPase targeting with disruption of pump-linked oncogenic signaling and, in some models, α1-subunit destabilization/degradation.</li>
<li>Mitochondria-linked apoptosis with cytochrome c release, caspase activation, and loss of survival signaling.</li>
<li>Suppression of PI3K/Akt/mTOR and related pro-survival nodes, with context-dependent effects on ERK, NF-κB, and STAT3-linked programs.</li>
<li>ROS elevation with stress-kinase activation (especially JNK/p38) and redox-dependent death signaling; this is important but usually downstream/secondary rather than the first initiating event.</li>
<li>Cell-cycle arrest and mitotic disruption, including Aurora kinase-related effects in some tumor models.</li>
<li>Inhibition of stemness, EMT, migration, invasion, angiogenesis, and drug-resistance phenotypes, including Wnt/β-catenin- and YAP-associated programs in selected cancers.</li>
<li>Autophagy modulation, which can be cytoprotective or cytotoxic depending on model and schedule.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> Translation is constrained by poor water solubility, low/variable bioavailability of bufadienolides, short apparent plasma persistence in human Huachansu infusion studies, and a narrow therapeutic window typical of cardiac glycosides. CYP3A-mediated metabolism and CYP3A4 inhibition/time-dependent inactivation raise drug-interaction concern. Delivery optimization by nanoparticles, prodrugs, and formulation engineering is mechanistically relevant, not merely cosmetic.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Concentration-driven. Many mechanistic cancer studies report activity in low-nanomolar to submicromolar ranges, which is closer to plausibility than for many phytochemicals; however, human plasma bufalin levels reported during Huachansu infusion were only low ng/mL and showed little accumulation, so many higher in-vitro conditions likely exceed sustained clinically achieved free exposure. Any interpretation should therefore prioritize low-nanomolar findings and delivery-enabled tumor exposure rather than high-concentration cell-culture effects.</p>

<p><b>Clinical evidence status:</b> <b>Preclinical to small-human evidence only.</b> There is substantial in-vitro and animal evidence, plus early Huachansu clinical studies in China and a phase I/II development path, but no convincing randomized evidence that bufalin-containing therapy improves major cancer outcomes. Current status is best described as <b>experimental / adjunct-oriented rather than established anticancer therapy</b>.</p>


<h3>Mechanistic translation matrix</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Na+/K+-ATPase signalosome</td>
<td>↓ pump-linked oncogenic signaling; ↓ proliferation; apoptosis trigger</td>
<td>↓ ubiquitous pump function; cardiotoxicity risk</td>
<td>P-R</td>
<td>Upstream target engagement</td>
<td>Most central mechanism. Bufalin behaves as a cardiac glycoside/bufadienolide with strong relevance to ATP1A1-linked signaling and tumor vulnerability, but normal-tissue exposure limits selectivity.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondria and intrinsic apoptosis</td>
<td>↑ cytochrome c release; ↑ caspases; ↑ mitochondrial dysfunction</td>
<td>↔ to ↓ tolerance window</td>
<td>R-G</td>
<td>Cell death induction</td>
<td>Robust across many tumor models and commonly downstream of Na+/K+-ATPase disruption, ROS stress, and survival-pathway collapse.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K Akt mTOR survival axis</td>
<td>↓</td>
<td>↔ to ↓</td>
<td>R-G</td>
<td>Anti-survival signaling</td>
<td>One of the most repeatedly reported downstream axes. Often linked to apoptosis sensitization, growth arrest, and resistance reversal.</td>
</tr>
<tr>
<td>4</td>
<td>NF-κB inflammatory survival signaling</td>
<td>↓</td>
<td>↔ to ↓</td>
<td>R-G</td>
<td>Reduced survival and inflammatory tone</td>
<td>Usually a secondary convergence node rather than the first molecular hit.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial ROS increase</td>
<td>↑ (dose-dependent)</td>
<td>↑ toxicity risk</td>
<td>R</td>
<td>Stress amplification</td>
<td>Mechanistically important in several models, especially where JNK/p38 activation and autophagy-mediated death are observed. Not universal as the dominant initiating event.</td>
</tr>
<tr>
<td>6</td>
<td>JNK p38 stress kinase axis</td>
<td>↑</td>
<td>↔</td>
<td>R-G</td>
<td>Pro-apoptotic stress signaling</td>
<td>Often coupled to ROS elevation and mitochondrial injury.</td>
</tr>
<tr>
<td>7</td>
<td>ERK MAPK signaling</td>
<td>↓ or ↔ (context-dependent)</td>
<td>↔</td>
<td>R-G</td>
<td>Growth signaling modulation</td>
<td>Reported direction varies by model; best treated as context-dependent rather than universally suppressed.</td>
</tr>
<tr>
<td>8</td>
<td>Cell-cycle and mitotic machinery</td>
<td>↑ G0/G1 or G2/M arrest; ↓ Aurora activation</td>
<td>↔ to ↓ proliferative tissues</td>
<td>G</td>
<td>Cytostasis and mitotic disruption</td>
<td>Relevant in multiple cancers; checkpoint phenotype varies by model.</td>
</tr>
<tr>
<td>9</td>
<td>Wnt β-catenin stemness axis</td>
<td>↓ stemness; ↓ EMT; ↓ invasion</td>
<td>↔</td>
<td>G</td>
<td>Anti-metastatic differentiation pressure</td>
<td>Important in selected resistant and stem-like states rather than universally core.</td>
</tr>
<tr>
<td>10</td>
<td>Autophagy program</td>
<td>↑ or ↓ (context-dependent)</td>
<td>↔</td>
<td>R-G</td>
<td>Death modulator</td>
<td>Can either support survival or contribute to death. Interpretation must stay model-specific.</td>
</tr>
<tr>
<td>11</td>
<td>Chemosensitization and resistance reversal</td>
<td>↑ sensitivity</td>
<td>↔</td>
<td>G</td>
<td>Adjunct potential</td>
<td>Preclinical evidence is strong enough to keep this high in translational interest, but human confirmation is still weak.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Exposure limited</td>
<td>Systemic toxicity relevant</td>
<td>G</td>
<td>Therapeutic window constraint</td>
<td>Poor solubility, formulation dependence, short plasma persistence, CYP3A liability, and cardiac-glycoside toxicity remain the main barriers to direct clinical deployment.</td>
</tr>
</table>
<p>P: 0–30 min<br>R: 30 min–3 hr<br>G: &gt;3 hr</p>